Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

T. Wada, Y. Yoshikawa, Naohisa Yahagi, N. Kawamura, N. Kakei, Y. Matsubara, M. Tsuji, K. Miki

Research output: Contribution to journalArticle

Abstract

The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

Original languageEnglish
Pages (from-to)219-232
Number of pages14
JournalJapanese Pharmacology and Therapeutics
Volume26
Issue numberSUPPL. 5
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Safety
Constipation
Diarrhea
calcium polycarbophil
Clinical Studies

Keywords

  • Calcium polycarbophil
  • Constipation
  • Diarrhea
  • Fine granule
  • Gastrointestinal symptoms
  • Irritable bowel syndrome
  • Stool disorders

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Wada, T., Yoshikawa, Y., Yahagi, N., Kawamura, N., Kakei, N., Matsubara, Y., ... Miki, K. (1998). Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. Japanese Pharmacology and Therapeutics, 26(SUPPL. 5), 219-232.

Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. / Wada, T.; Yoshikawa, Y.; Yahagi, Naohisa; Kawamura, N.; Kakei, N.; Matsubara, Y.; Tsuji, M.; Miki, K.

In: Japanese Pharmacology and Therapeutics, Vol. 26, No. SUPPL. 5, 1998, p. 219-232.

Research output: Contribution to journalArticle

Wada, T, Yoshikawa, Y, Yahagi, N, Kawamura, N, Kakei, N, Matsubara, Y, Tsuji, M & Miki, K 1998, 'Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome', Japanese Pharmacology and Therapeutics, vol. 26, no. SUPPL. 5, pp. 219-232.
Wada T, Yoshikawa Y, Yahagi N, Kawamura N, Kakei N, Matsubara Y et al. Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. Japanese Pharmacology and Therapeutics. 1998;26(SUPPL. 5):219-232.
Wada, T. ; Yoshikawa, Y. ; Yahagi, Naohisa ; Kawamura, N. ; Kakei, N. ; Matsubara, Y. ; Tsuji, M. ; Miki, K. / Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. In: Japanese Pharmacology and Therapeutics. 1998 ; Vol. 26, No. SUPPL. 5. pp. 219-232.
@article{6886bc593c284fe7b7d089015475b18a,
title = "Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome",
abstract = "The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1{\%} (13/22) and 68.2{\%} (15/22), respectively. The rates in the final global improvement was 68.2{\%} (15/22). The rates in the diarrhea and constipation predominant cases were 66.7{\%} (12/18) and 75.0{\%} (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0{\%} (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0{\%} (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6{\%} (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.",
keywords = "Calcium polycarbophil, Constipation, Diarrhea, Fine granule, Gastrointestinal symptoms, Irritable bowel syndrome, Stool disorders",
author = "T. Wada and Y. Yoshikawa and Naohisa Yahagi and N. Kawamura and N. Kakei and Y. Matsubara and M. Tsuji and K. Miki",
year = "1998",
language = "English",
volume = "26",
pages = "219--232",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

AU - Wada, T.

AU - Yoshikawa, Y.

AU - Yahagi, Naohisa

AU - Kawamura, N.

AU - Kakei, N.

AU - Matsubara, Y.

AU - Tsuji, M.

AU - Miki, K.

PY - 1998

Y1 - 1998

N2 - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

AB - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

KW - Calcium polycarbophil

KW - Constipation

KW - Diarrhea

KW - Fine granule

KW - Gastrointestinal symptoms

KW - Irritable bowel syndrome

KW - Stool disorders

UR - http://www.scopus.com/inward/record.url?scp=0031791512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031791512&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031791512

VL - 26

SP - 219

EP - 232

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - SUPPL. 5

ER -